HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 259 filers reported holding HAEMONETICS CORP in Q2 2021. The put-call ratio across all filers is 1.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,660,020 | -21.3% | 119,000 | -25.2% | 0.46% | -20.3% |
| Q2 2023 | $13,537,260 | +2.9% | 159,000 | 0.0% | 0.57% | -0.9% |
| Q1 2023 | $13,157,250 | -9.1% | 159,000 | -13.6% | 0.58% | -12.3% |
| Q4 2022 | $14,471,600 | +6.2% | 184,000 | 0.0% | 0.66% | -6.1% |
| Q3 2022 | $13,622,000 | +10.6% | 184,000 | -2.6% | 0.70% | +16.9% |
| Q2 2022 | $12,319,000 | +3.1% | 189,000 | 0.0% | 0.60% | +19.3% |
| Q1 2022 | $11,949,000 | +63.2% | 189,000 | +37.0% | 0.50% | +76.8% |
| Q4 2021 | $7,320,000 | -5.7% | 138,000 | +25.5% | 0.28% | -11.0% |
| Q3 2021 | $7,765,000 | +29.5% | 110,000 | +22.2% | 0.32% | +31.8% |
| Q2 2021 | $5,998,000 | -10.0% | 90,000 | +50.0% | 0.24% | -16.3% |
| Q1 2021 | $6,661,000 | -6.5% | 60,000 | 0.0% | 0.29% | -10.5% |
| Q4 2020 | $7,125,000 | +63.3% | 60,000 | +20.0% | 0.32% | +46.8% |
| Q3 2020 | $4,363,000 | +94.9% | 50,000 | +100.0% | 0.22% | +81.8% |
| Q2 2020 | $2,239,000 | – | 25,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
| Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
| HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
| Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
| Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
| Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
| ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
| CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
| Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |